Drug-resistant virus treatment market seen topping $14.69 billion by 2030

The drug resistant virus treatment market is projected to grow from $9.42 billion in 2025 to $14.69 billion by 2030, driven by rising antiviral resistance and demand for multi-mechanism therapies. Asia-Pacific led the market in 2025 and is expected to remain the fastest-growing region.

Why it matters: - Rising antiviral resistance is making some standard treatments less effective and increasing the need for new therapies. - The market’s projected growth points to more spending on precision antivirals, resistance tracking, and combination treatments.

What happened: - The Business Research Company said the drug resistant virus treatment market will rise from $9.42 billion in 2025 to $10.28 billion in 2026. - The company projects the market will reach $14.69 billion by 2030, reflecting a 9.3% CAGR from 2026 to 2030. - The report was released July 1, 2026, from London. - The report is available here.

The details: - The market’s recent growth has been driven by limited antiviral options, rising resistance in HIV and hepatitis, and heavy reliance on single-mechanism therapies. - Enhanced outbreak surveillance and stronger hospital infectious disease protocols have also supported demand. - The report defines drug resistant virus treatment as medical approaches, therapies and pharmaceutical products used when standard antiviral drugs no longer work. - The main goal is to control resistant viral strains while limiting further mutation and transmission. - The report cites a WHO projection from November 2025 that resistance to Dolutegravir among HIV patients failing DTG-based ART could rise from 18% in 2023 to 42% by 2035 without intervention. - Asia-Pacific was the largest regional market in 2025 and is expected to grow the fastest during the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, North America, South America, and the Middle East and Africa.

Between the lines: - The forecast suggests drug resistance is shifting from a niche clinical problem to a broader commercial opportunity for diagnostics, rescue therapies and broader-spectrum antivirals. - The strongest growth themes point to personalized care, especially resistance profiling and genomic monitoring, rather than one-size-fits-all antiviral treatment. - Investment interest appears to be moving toward monoclonal antibodies, adaptive trials and combination regimens that can respond faster to evolving strains.

What's next: - The report expects next-generation combination antiviral therapies to gain traction during the forecast period. - Broad-spectrum antiviral resistance inhibitors, personalized diagnostics and adaptive clinical trial designs are also expected to expand. - Monoclonal antibody-based rescue treatments are likely to become more common as resistant strains spread. - The market is expected to benefit from broader pandemic preparedness efforts and continued work on genomic resistance tracking.

The bottom line: - Drug-resistant viral infections are creating a durable demand story for treatment developers, with market growth tied to faster diagnostics, multi-drug approaches and better resistance monitoring.